Literature DB >> 27554802

Targeting the endocannabinoid system: future therapeutic strategies.

Oier Aizpurua-Olaizola1, Izaskun Elezgarai2, Irantzu Rico-Barrio2, Iratxe Zarandona3, Nestor Etxebarria3, Aresatz Usobiaga3.   

Abstract

The endocannabinoid system (ECS) is involved in many physiological regulation pathways in the human body, which makes this system the target of many drugs and therapies. In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs. In addition, we propose some key steps, such as the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27554802     DOI: 10.1016/j.drudis.2016.08.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  39 in total

1.  Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation.

Authors:  Julie T Castaneda; Airi Harui; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-31       Impact factor: 4.147

2.  Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.

Authors:  Jasmine Turna; Sabrina K Syan; Benicio N Frey; Brian Rush; Mary Jean Costello; Mark Weiss; James MacKillop
Journal:  Alcohol Clin Exp Res       Date:  2019-02-19       Impact factor: 3.455

Review 3.  G protein-coupled receptors in acquired epilepsy: Druggability and translatability.

Authors:  Ying Yu; Davis T Nguyen; Jianxiong Jiang
Journal:  Prog Neurobiol       Date:  2019-08-24       Impact factor: 11.685

4.  Priorities for Medical Marijuana Research from the Perspective of Physicians, Dispensary Owners/Staff, and Patients: A Survey Study.

Authors:  Jennifer Jean-Jacques; Robert Cook; Almut G Winterstein; Amie Goodin; Joshua D Brown; Sebastian Jugl; Yan Wang
Journal:  Med Cannabis Cannabinoids       Date:  2021-08-02

5.  Endocannabinoids as potential biomarkers: It's all about pre-analytics.

Authors:  Daniel Kratz; Dominique Thomas; Robert Gurke
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-10

6.  Identification of CB1 Ligands among Drugs, Phytochemicals and Natural-Like Compounds: Virtual Screening and In Vitro Verification.

Authors:  Adam Stasiulewicz; Anna Lesniak; Piotr Setny; Magdalena Bujalska-Zadrożny; Joanna I Sulkowska
Journal:  ACS Chem Neurosci       Date:  2022-10-05       Impact factor: 5.780

7.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

8.  Morphine Induces Upregulation of Neuronally Expressed CB2 Receptors in the Spinal Dorsal Horn of Rats.

Authors:  Patrick Grenier; Adam Sunavsky; Mary C Olmstead
Journal:  Cannabis Cannabinoid Res       Date:  2021-04-15

9.  Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.

Authors:  M Galán-Ganga; C Rodríguez-Cueto; J Merchán-Rubira; F Hernández; J Ávila; M Posada-Ayala; J L Lanciego; E Luengo; M G Lopez; A Rábano; J Fernández-Ruiz; I Lastres-Becker
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

10.  Potassium channels as molecular targets of endocannabinoids.

Authors:  Yu-Fung Lin
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.